1 Clark Memorial Community Hospital, Jeffersonville, IN, USA.
2 Purdue University College of Pharmacy, Indianapolis, IN, USA.
Ann Pharmacother. 2019 Mar;53(3):276-284. doi: 10.1177/1060028018799982. Epub 2018 Sep 6.
To review the efficacy, safety, and place in therapy of ixekizumab for the treatment of moderate to severe plaque psoriasis.
PubMed (1966 to July 2018) and clinicaltrials.gov were searched using the terms ixekizumab, LY2439821, interleukin-17, and psoriasis.
Human studies published in peer-reviewed medical journals in English were used.
The efficacy and safety of ixekizumab has been primarily reported by 4 phase III trials (UNCOVER-1, UNCOVER-2, UNCOVER-3, and UNCOVER-J) and multiple post hoc analyses. The average proportions of patients achieving a 75%, 90%, and 100% reduction in their Psoriasis Area and Severity Index (PASI) were 89%, 70%, and 38%, respectively, after 12 weeks of therapy. PASI75 was maintained for up to 3 years in 80.5% of participants. Ixekizumab was statistically significantly more effective than ustekinumab, with 76.5%, compared with 59%, of patients achieving PASI90 in 52 weeks. The most common adverse events include nasopharyngitis (14.1%), upper respiratory tract infections (7.9%), and injection-site reactions (6.8%), which are similar to that for other biological agents. The risk of inflammatory bowel disease may be increased with ixekizumab. Relevance to Patient Care and Clinical Practice: This review summarizes and evaluates clinical data regarding the efficacy and safety of ixekizumab and discusses relevant differences compared with other biological agents used for the management of chronic plaque psoriasis.
Ixekizumab is a highly efficacious and well-tolerated treatment option for patients with moderate to severe plaque psoriasis.
综述依奇珠单抗治疗中重度斑块型银屑病的疗效、安全性和临床地位。
在 PubMed（1966 年至 2018 年 7 月）和 clinicaltrials.gov 上，使用 ixekizumab、LY2439821、白细胞介素-17 和银屑病等术语进行检索。
使用在同行评议医学期刊上发表的英文人类研究。
依奇珠单抗的疗效和安全性主要由 4 项 III 期试验（UNCOVER-1、UNCOVER-2、UNCOVER-3 和 UNCOVER-J）和多次事后分析报告。治疗 12 周后，分别有 89%、70%和 38%的患者达到了银屑病面积和严重程度指数（PASI）减少 75%、90%和 100%。80.5%的患者在 3 年内保持了 PASI75。与 ustekinumab 相比，依奇珠单抗治疗 52 周后达到 PASI90 的患者比例分别为 76.5%和 59%，具有统计学显著差异。最常见的不良事件包括鼻咽炎（14.1%）、上呼吸道感染（7.9%）和注射部位反应（6.8%），与其他生物制剂相似。依奇珠单抗可能会增加炎症性肠病的风险。
本综述总结和评估了依奇珠单抗的疗效和安全性的临床数据，并讨论了与用于治疗慢性斑块型银屑病的其他生物制剂相比的相关差异。
依奇珠单抗是治疗中重度斑块型银屑病患者的一种高效且耐受性良好的治疗选择。
